Abstract
BACKGROUND: There is mounting evidence that Circular RNAs (circRNAs) are essential for the initiation and development of gastric cancer (GC). In this study, we further investigated the clinical importance and applicability of serum hsa_circ_0000702 in the diagnosis and treatment of GC. METHODS: Sanger sequencing, agarose gel electrophoresis, and RNase R assay were used to confirm the origin, alterations, and stability of hsa_circ_0000702 in GC patients. Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to detect the expression level of hsa_circ_0000702 in GC cell lines, serum, and tissues. Additionally, receiver operating characteristic (ROC) curves were built to evaluate their prognostic value and how well they would work in conjunction with popular biochemical markers for GC. Finally, real-time dynamic monitoring was used to assess its prognostic usefulness. RESULTS: Hsa_circ_0000702 exhibited the fundamental traits of circRNA. Hsa_circ_0000702 had good sensitivity, specificity, and stability. It was discovered that hsa_circ_0000702 was down-regulated in GC cell lines, serum, and tissues, and that the level of tumor differentiation and tumor node metastasis (TNM) staging were connected with serum hsa_circ_0000702. The area under the ROC curve of serum hsa_circ_0000702 was calculated to be 0.745 (95% CI: 0.669-0.821), indicating high diagnostic efficacy. The diagnostic value was greatly increased by combining serum CEA and CA19-9. Finally, preoperative and postoperative dynamic monitoring revealed serum hsa_circ_0000702 to be of clinical application. CONCLUSION: Serum hsa_circ_0000702 was variably expressed in GC patients, indicating that serum hsa_circ_0000702 may be a novel biomarker for GC diagnosis and dynamic monitoring.